A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

NCT01614522 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasms
Cancer of Stomach
Cancer of the Stomach
Gastric Cancer
Gastric Neoplasms

Interventions

DRUG: ASLAN001

Sponsor

ASLAN Pharmaceuticals